Phibro Animal Health Corp. (NASDAQ:PAHC)’s share price rose 2.5% during trading on Wednesday . The stock traded as high as $21.51 and last traded at $21.44, with a volume of 67,284 shares. The stock had previously closed at $20.92.

PAHC has been the topic of several recent research reports. TheStreet lowered Phibro Animal Health Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, June 9th. Zacks Investment Research downgraded Phibro Animal Health Corp. from a “hold” rating to a “sell” rating in a report on Tuesday. Morgan Stanley restated a “sell” rating on shares of Phibro Animal Health Corp. in a report on Thursday, May 12th. Finally, Guggenheim restated a “buy” rating and set a $26.00 price objective (down from $34.00) on shares of Phibro Animal Health Corp. in a report on Friday, May 13th. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $35.33.

The stock has a market capitalization of $825.97 million and a price-to-earnings ratio of 10.74. The firm’s 50 day moving average price is $20.60 and its 200 day moving average price is $22.49.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 28th. Shareholders of record on Wednesday, September 7th will be given a $0.10 dividend. This represents a $0.40 annualized dividend and a yield of 1.91%. The ex-dividend date of this dividend is Friday, September 2nd.

Phibro Animal Health Corporation is an animal health and mineral nutrition company. The Company is engaged in developing, manufacturing and marketing products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The Company operates through three segments: Animal Health, Mineral Nutrition and Performance Products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.